Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis
Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV
Shots:
- NICE has recommended Cosentyx as a cost-effective option for the treatment of mod. to sev. PsO in patients aged 6-17 yrs. who have not responded to other forms of systemic treatment & for whom these options were contraindicated or not tolerated
- Additionally, patients will now have access to this treatment option on the NHS. The therapy is supported through the sustained efficacy and safety data across psoriasis, PsA, and axSpA with 500,000+ patients treated globally
- Secukinumab (SC, q4w) is the first IL-17A inhibitor to be recommended by NICE & is approved in 90+ countries including the UK, in EU, US, Japan & China
Click here to read full press release/ article | Ref: Novartis | Image: Reuters